Laboratorios Rovi and HM Hospitales partner to conduct clinical trial on the efficacy of Bemiparin in patients with Covid-19
Laboratorios Rovi y HM Hospitales se alían para realizar un ensayo clínico sobre la eficacia de Bemiparina en pacientes con Covid-19
Intel ID : 296828
Relevant Documents
| Press Release | 14 Apr 2020 | Laboratorios_Rovi_Nota_de_Prensa_2020.pdf | ES |
|
| Intel ID | 296828 | ||
| Value | ND | ||
| Native Currency | Euro (EUR) | ||
|
Financial Data - Laboratorios Rovi
(31 Dec 2023) |
Revenue: - EBITDA: - Net Debt: - |
||
| Date |
 |
||
| Country |  |
||
| Geography | |
||
| Subsector (Old TTR Sectors) |
|
||
| Type |
|
||
| Intel Grade |
|
||
| Source |
|
||
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.03.08 Hospitals 30 Healthcare / 30.03 Healthcare Facilities & Services |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.